Skip to main content

Devgen Creates C. elegans RNA Interference Library

NEW YORK, Feb. 22 - Belgian functional genomics company Devgen on Friday said it has created a complete C. elegans RNA interference library.

The library is genome-wide, including complexes that can suppress the activity of each of the 19,000 C. elegans genes. Devgen plans to use the library in drug-target identification and functional validation.

 

RNAi is a form of post-transcriptional gene silencing that works by targeting and cleaving endogenous mRNA.

 

Devgen, based in Ghent, uses C. elegans as a model for target and drug discovery. It uses RNAi knockdown technology in the worm to evaluate gene function, and combines that technique with a comparative-genomics approach to understand human homologues of disease pathways.

 

The company, which employs about 90 people, is privately held. It has partnerships with Princeton, NJ-based  FMC Corp. for new pesticide discovery, and with Metabolex for diabetes research.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.